Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lafutidine vs Famotidine in Mild Reflux Oesophagitis
NCT00229424Phase 3Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Apr 2005
- Primary completion
- Oct 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lafutidine in reflux esophagitis (3 arms), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoint: Endoscopic healing rate at 8 weeks. Started Apr 2005; status: completed.
02
Drugs
lafutidine
03
Conditions
reflux esophagitis
Beyond the preview
Go deeper on NCT00229424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00229424.